The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.
July 18th 2025
Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
Understand how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity through a shift of reactive to proactive care that addresses root causes of cardiometabolic disease.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Report Says US Dietary Panel Poised to Drop Warning on Cholesterol
Lilly's Glyxambi, First-in-Class Combination Pill, Approved for T2DM